top of page

NEWS and PRESS RELEASES

DL square for CEBINA website.png

12 September 2023

Danube Labs: Call for Proposals - September 2023
Read more

 

CEBINA covid square.png

04 July 2022

CEBINA publishes data demonstrating the anti-histamine azelastine inhibits infection by  major variants of SARS-CoV-2
Read more

CEBINA covid square.png

03 February 2022

Azelastine - the active drug in anti-allergy nasal sprays demonstrated to have potent anti-viral effect on the Omicron variant of
SARS-CoV-2
Read more

CEBINA covid square.png

02 May 2023

CEBINA Announces Positive Results of a Phase 2 Clinical Study with COVID-19 patients and Azelastine Nasal Spray Published in a Peer-Reviewed Scientific Journal
Read more

DL square for CEBINA website.png

19 April 2022

Danube Labs: Call for Proposals
Read more

 

CEBINA covid square.png

10 December 2021

CEBINA reports broad anti-viral potency of azelastine, an antihistamine widely available as a nasal spray, has potential for use against influenza and RSV infections in addition to SARS-CoV-2 and its variants of concern including the Omicron variant
Read more

DL square for CEBINA website.png

07 March 2023

Danube Labs: Call for Proposals - April 2023
Read more

 

EVQ%20green%20square_edited.jpg

23 February 2022

Eveliqure announces the publication of positive Phase I clinical data for its vaccine candidate against Shigellosis and ETEC
Read more

CEBINA covid square.png

17 August 2021

Widely available anti-allergy azelastine nasal spray poised to revolutionize COVID-19 management
Read more

 

bottom of page